Astellas Pharma Inc (ALPMF) 13.4799 $ALPMF
Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies
PR Newswire - Fri Oct 09, 7:15AM CDT
Immunomic Therapeutics, Inc. ("ITI"
, a privately-held biotechnology company developing next generation vaccines based on the LAMP-vax platform, today announced that it has entered into an exclusive worldwide licensing agreement with Astellas Pharma Inc. on LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. Upon execution of the agreement, Immunomic Therapeutics will receive an upfront payment of $300 million and be entitled to receive 10 percent royalties based on net sales of the potential products for allergic diseases while retaining the rights to the LAMP-vax platform for other applications, including cancer immunotherapy.
Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax(TM) Products for Allergic Disease
PR Newswire - Fri Oct 09, 7:00AM CDT
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics" , a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas" today announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. The LAMP-vax technology enhances the effectiveness of DNA vaccines. It has the ability to make DNA vaccines work, which potentially enables effective vaccinations for a wide spectrum of diseases.
Astellas Pharma Canada, Inc. Partners with Canadian Society of Transplantation
CNW Group - Thu Oct 08, 8:00AM CDT
Partnership establishes grant to advance immunology research in Canada
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Global Chemotherapy Induced Nausea and Vomiting Pipeline Review, H2 2015 - 13 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk65k/chemotherapy) has announced the addition of the "Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acacia Pharma Limited - Aphios Corporation - Astellas Pharma Inc. - Helsinn Healthcare S.A. - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Co., Inc. - RedHill Biopharma Ltd. - SoluBest Ltd. - Suda Ltd - Teikoku Pharma USA, Inc. - Tesaro, Inc. Drug Profiles - (netupitant palonosetron hydrochloride) - APD-403 - aprepitant - dronabinol - FK-886 - granisetron ER - granisetron hydrochloride ER - netupitant - ondansetron hydrochloride - ondansetron hydrochloride CR - rolapitant hydrochloride - TPW-146 For more information visit http://www.researchandmarkets.com/research/kk...emotherapy
INSY: 25.65 (+0.64), TSRO: 45.96 (+3.22), RDHL: 12.80 (+0.53), HRTX: 25.72 (-0.93), MRK: 50.95 (-0.07)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Urinary Incontinence - Pipeline Review, H2 2015
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwlrf3/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Astellas Pharma Inc. - Celogos - Cook MyoSite Incorporated - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - TheraVida, Inc. Drug Profiles - (mirabegron solifenacin succinate) - ASP-2205 - ASP-5633 - Cell Therapy for Urinary Incontinence - ICES-13 - oxybutynin hydrochloride - Prof-003 - RCD-1 - senrebotase - Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - THVD-201 - THVD-202 For more information visit http://www.researchandmarkets.com/research/jwlrf3/urinary
AGN: 274.84 (-1.32)
Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
PR Newswire - Wed Sep 30, 12:00AM CDT
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" and Chromocell Corporation (CEO: Christian Kopfli, "Chromocell" today announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions.
Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market 2015 - Forecasts to 2025
M2 - Mon Sep 28, 7:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shj6wk/adc_contract) has announced the addition of the "ADC Contract Manufacturing Market (2nd edition), 2015-2025" report to their offering. Antibody Drug Conjugates (ADCs) are a new class of therapeutic drugs consisting of a cytotoxic drug linked to a monoclonal antibody. These novel conjugates are believed to be very effective and efficient in treatment of a disease. However, manufacturing such highly potent toxic molecules is accompanied with several known and unknown challenges. In-house manufacturing of ADCs is rare primarily because of the complex nature of these molecules. Their manufacturing requires both clean room biologic and high containment cytotoxic facilities. This combination is rare and difficult to achieve, requiring significant capital investment. Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk. Even the leading technology providers, including Seattle Genetics and ImmunoGen, are dependent on contract manufacturers to supply the components. Despite the fact that some developers (e.g. Roche) have recently announced their plans to build in-house facilities, the trend of outsourcing is likely to continue for at least the coming decade. It is worth highlighting there has been a surge in investment activity for facility expansions by a number of CMOs. The concept of one-stop-shop is also gaining traction as CMOs have collaborated with one another in an effort to cater to the increasing demand and to streamline the manufacturing process under one umbrella. Although there are two marketed ADCs till date, a rich and extensive pipeline presents a very big opportunity for the contract manufacturers. The report provides an extensive study of the contract manufacturing opportunity for the emerging class of ADCs. The report covers various aspects, such as identifying CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities. The base year for the report is 2015. The report provides short-mid term and long term market forecasts for the period 2015 - 2020 and 2020 - 2025, respectively. We have discussed, in detail, the key drivers behind the growth of the ADC contract manufacturing market. The research, analysis and insights presented in this report are backed by a comprehensive survey on ADC manufacturing capabilities of several CMOs. In addition, we interviewed important stakeholders to solicit their opinions around the future opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Piramal Healthcare, Pierre Fabre, Catalent, Lonza and BSP Pharmaceuticals. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. ADC Therapeutics: Development Overview 5. Manufacturing of ADCs: A Market Overview 6. CMOs: Worldwide Landscape 7. Profiles of Leading Companies 8. Recent Developments 9. Market Size and Forecast 10. SWOT Analysis 11. Conclusion 12. Interview Transcripts 13. Appendix 1: Tabulated Data 14. Appendix 2: List of Companies and Organisations Companies Mentioned - 35 of the 100 Companies - AAIPharma Services Corp - Ambrx - Amgen - AMRI Global - Aspyrian Therapeutics - Astellas Pharma/Agensys - Asymchem - Baxter BioPharma Solutions - Bayer Healthcare - Cambrex Corporation - CARBOGEN AMCIS - DSM Pharmaceuticals - EirGenix - Eli Lilly - Endo Pharmaceuticals - GSK - Heidelberg Pharma - Heraeus Precious Metals - iBIOSOURCE - Mersana Therapeutics - Millennium - MiMabs - National Cancer Institute - National Research Council Canada - NBE Therapeutics - Novartis - Pfizer/Wyeth - Philochem - Pierre Fabre - Redwood Bioscience - Roche/Genentech - SafeBridge Consultants - Sandoz - Sanofi - Zymeworks For more information visit http://www.researchandmarkets.com/research/sh...c_contract
ENDP: 64.27 (+0.85), CBM: 43.23 (-0.03), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), NVS: 91.90 (-0.71)
Liver Cirrhosis Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbjtw7/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H1, 2015" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H1, 2015" provides an overview of Liver Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Astellas Pharma - C. H. Boehringer Sohn - Conatus Pharmaceuticals - F. Hoffmann-La Roche - Genextra - GlaxoSmithKline - Merck & Co. - Novartis - Sanofi - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/zb..._cirrhosis
MRK: 50.95 (-0.07), CNAT: 4.21 (-0.06), GSK: 40.22 (+0.06), VRX.TO: 227.56 (+4.67), NVS: 91.90 (-0.71)
Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbnk43/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" report to their offering. This clinical trial report, Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" provides an overview of Herpes Zoster (Shingles) clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Astellas Pharma - Boehringer Ingelheim - GlaxoSmithKline - Hammersmith Medicines Research - Maruho - Merck & Co. - NeurogesX - Pfizer - Synergy Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pb...pes_zoster
SGYP: 6.32 (+0.18), MRK: 50.95 (-0.07), GSK: 40.22 (+0.06)
Zen & The Technology of Japanese Packaging Design Report 2015 - 2012-2014 Analysis of the $59 Billion Industry Featuring over 100 Manufacturers
M2 - Thu Sep 24, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g84x48/zen_and_the) has announced the addition of the "Zen & The Technology of Japanese Packaging Design 2012-14" report to their offering. The ultimate illustrated guide to current trends in Japan's US$59.4 billion product packaging market. This 202-page report examines changing consumer trends and the regulatory environment for all key packaging end-use markets - food, beverage, spirits, confectionery, cosmetics, personal care, household, pharmaceutical, medical, electronics, industrial and logistics - and all packaging materials, types and formats. Fully illustrated with more than 200 photographs of the latest innovative packaging technologies and solutions introduced in the Japanese market between 2012 and 2014 by more than 110 Japanese packaging manufacturers, design agencies and brand owners, Zen & The Technology of Japanese Packaging Design 2012-14 provides real-life market examples and case studies of how the Japanese packaging industry has responded to the changing market dynamic. Many of the product packaging solutions developed by Japanese industry are relevant in Western markets where packaging and brand owners are begining to encounter similar challenges of changing demographics, sustainability and increased regulatory regimens. Why Purchase this Report: - Understand the cultural cues underlying product packaging in Japan - Be inspired by the simplicity of minute market-oriented attention to detail - Find out how to sell to Japanese consumers, and by extension, other Asian markets - Gain knowledge about the impact of Japan's legislation on packaging design - See how the EU's Circular Economy Package, when passed, could impact packaging conceptualisation and production - Learn how sustainable packaging can be achieved without compromising design integrity - Discover an entirely new market niche by planning Accessibility and Universal Design into your production workflow - Be inspired by ideas for your own design project Key Topics Covered: 1. Introduction: A Narrow Road to the Deep North 2. Aesthetics & Zen 3. Referencing EDO 4. The Japanese Packaging Industry Structure: 5. Packaging the Environment 6. A Circular Economy 7. Marketing & the New Demographic 8. Universal Design 9. Japan's Retail Revolution 10. Packaging & Disaster Companies Mentioned - Partial List - Able Design - Ailop Corp - Ajinomoto - Aoki Laboratories Ltd - Asahi Breweries Ltd - Asahi Kasei Pax Corporation - Asahi Printing Co Ltd - Astellas Pharma Inc - Ito-Takaya Design Office Inc - Japan Gateway Co Ltd - Japan Packaging Institute - Japansalt Corporation - Johnson Co Ltd - J-Oil Mills Inc - Kabaya Confectionery Co Ltd - Kanpyo Corporation - Lion Corporation - Mitsubishi Shoji Packaging Corporation - Mottainai - Nabatame Design Co Ltd - Nakatsugawa Packaging Industrial Co Ltd - Nestle Japan Ltd - Nestl? Japan Ltd - Next Innovation Inc - Oji Container Co Ltd - Oji Paper Co Ltd - PacPlus Co Ltd - Takeda Sangyo Corporation Ltd - Teva Pharma Japan Inc - The Pack Corp - Three R Produce Inc - Toto Ltd - Toyo Seikan Kaisha Ltd - Yatsushika Brewery Co Ltd - Yoshida Cosmeworks Co Ltd For more information visit http://www.researchandmarkets.com/research/g8...en_and_the
GSVC: 8.26 (+0.05)
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 269.16 (-10.72), ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AVEO: 1.27 (+0.05), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
leon-nanodrugs GmbH Starts U.S. Operations and Appoints Industry Veteran Theron (Ted) Odlaug as Chief Executive Officer
PR Newswire Europe - Mon Sep 21, 1:00AM CDT
leon-nanodrugs GmbH today announced the appointment of industry veteran Theron (Ted) Odlaug, Ph.D. as the CEO for the leon-nanodrugs GmbH in Munich, Germany, and of its newly formed U.S. subsidiary leon-nanodrugs Inc., with offices in New York City and Chicago, Illinois. Recently, leon-nanodrugs successfully completed a Series A Financing round and announced using the proceeds to expand its profitable service business and to enter into high margin service and co-development deals with pharmaceutical partners.
AMRI: 17.28 (+0.08)
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
PR Newswire Europe - Fri Sep 18, 3:00AM CDT
CHERTSEY, England, September 18, 2015 /PRNewswire/ --
Astellas Pharma EMEA appoints Eugene Van Rensburg as Chief Financial Officer
M2 - Fri Sep 18, 2:45AM CDT
Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Eugene Van Rensburg to the position of Chief Financial Officer from his previous role as Senior Finance Director.
Jamie McGarvey joins Astellas Pharma Corporate Affairs Team
PR Newswire - Tue Sep 15, 3:00PM CDT
Astellas Pharma today announced that Jamie McGarvey has been named to the role of senior manager, employee communications within the Corporate Affairs Department. She will report to Jennifer Saputo, associate director of employee communications.
Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397
GlobeNewswire - Tue Sep 15, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present a poster summarizing results from preclinical studies of its antifungal compound, VL-2397 (formerly known as ASP2397), at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy joint meeting in San Diego, California. The poster, titled "Pharmacokinetic and Pharmacodynamic Characterization of ASP2397, a Novel Potent Antifungal Agent with Activity against Invasive Pulmonary Aspergillosis," will be presented during the "New Anti-Fungal Agents" poster session on September 19, 2015 from 11:00am to 1:00pm PT.
VICL: 0.43 (unch)
Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies
PR Newswire - Fri Oct 09, 7:15AM CDT
Immunomic Therapeutics, Inc. ("ITI"
, a privately-held biotechnology company developing next generation vaccines based on the LAMP-vax platform, today announced that it has entered into an exclusive worldwide licensing agreement with Astellas Pharma Inc. on LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. Upon execution of the agreement, Immunomic Therapeutics will receive an upfront payment of $300 million and be entitled to receive 10 percent royalties based on net sales of the potential products for allergic diseases while retaining the rights to the LAMP-vax platform for other applications, including cancer immunotherapy. Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax(TM) Products for Allergic Disease
PR Newswire - Fri Oct 09, 7:00AM CDT
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"
, a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas" today announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. The LAMP-vax technology enhances the effectiveness of DNA vaccines. It has the ability to make DNA vaccines work, which potentially enables effective vaccinations for a wide spectrum of diseases. Astellas Pharma Canada, Inc. Partners with Canadian Society of Transplantation
CNW Group - Thu Oct 08, 8:00AM CDT
Partnership establishes grant to advance immunology research in Canada
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Global Chemotherapy Induced Nausea and Vomiting Pipeline Review, H2 2015 - 13 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk65k/chemotherapy) has announced the addition of the "Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acacia Pharma Limited - Aphios Corporation - Astellas Pharma Inc. - Helsinn Healthcare S.A. - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Co., Inc. - RedHill Biopharma Ltd. - SoluBest Ltd. - Suda Ltd - Teikoku Pharma USA, Inc. - Tesaro, Inc. Drug Profiles - (netupitant palonosetron hydrochloride) - APD-403 - aprepitant - dronabinol - FK-886 - granisetron ER - granisetron hydrochloride ER - netupitant - ondansetron hydrochloride - ondansetron hydrochloride CR - rolapitant hydrochloride - TPW-146 For more information visit http://www.researchandmarkets.com/research/kk...emotherapy
INSY: 25.65 (+0.64), TSRO: 45.96 (+3.22), RDHL: 12.80 (+0.53), HRTX: 25.72 (-0.93), MRK: 50.95 (-0.07)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Urinary Incontinence - Pipeline Review, H2 2015
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwlrf3/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Astellas Pharma Inc. - Celogos - Cook MyoSite Incorporated - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - TheraVida, Inc. Drug Profiles - (mirabegron solifenacin succinate) - ASP-2205 - ASP-5633 - Cell Therapy for Urinary Incontinence - ICES-13 - oxybutynin hydrochloride - Prof-003 - RCD-1 - senrebotase - Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - THVD-201 - THVD-202 For more information visit http://www.researchandmarkets.com/research/jwlrf3/urinary
AGN: 274.84 (-1.32)
Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
PR Newswire - Wed Sep 30, 12:00AM CDT
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
and Chromocell Corporation (CEO: Christian Kopfli, "Chromocell" today announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions. Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market 2015 - Forecasts to 2025
M2 - Mon Sep 28, 7:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shj6wk/adc_contract) has announced the addition of the "ADC Contract Manufacturing Market (2nd edition), 2015-2025" report to their offering. Antibody Drug Conjugates (ADCs) are a new class of therapeutic drugs consisting of a cytotoxic drug linked to a monoclonal antibody. These novel conjugates are believed to be very effective and efficient in treatment of a disease. However, manufacturing such highly potent toxic molecules is accompanied with several known and unknown challenges. In-house manufacturing of ADCs is rare primarily because of the complex nature of these molecules. Their manufacturing requires both clean room biologic and high containment cytotoxic facilities. This combination is rare and difficult to achieve, requiring significant capital investment. Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk. Even the leading technology providers, including Seattle Genetics and ImmunoGen, are dependent on contract manufacturers to supply the components. Despite the fact that some developers (e.g. Roche) have recently announced their plans to build in-house facilities, the trend of outsourcing is likely to continue for at least the coming decade. It is worth highlighting there has been a surge in investment activity for facility expansions by a number of CMOs. The concept of one-stop-shop is also gaining traction as CMOs have collaborated with one another in an effort to cater to the increasing demand and to streamline the manufacturing process under one umbrella. Although there are two marketed ADCs till date, a rich and extensive pipeline presents a very big opportunity for the contract manufacturers. The report provides an extensive study of the contract manufacturing opportunity for the emerging class of ADCs. The report covers various aspects, such as identifying CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities. The base year for the report is 2015. The report provides short-mid term and long term market forecasts for the period 2015 - 2020 and 2020 - 2025, respectively. We have discussed, in detail, the key drivers behind the growth of the ADC contract manufacturing market. The research, analysis and insights presented in this report are backed by a comprehensive survey on ADC manufacturing capabilities of several CMOs. In addition, we interviewed important stakeholders to solicit their opinions around the future opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Piramal Healthcare, Pierre Fabre, Catalent, Lonza and BSP Pharmaceuticals. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. ADC Therapeutics: Development Overview 5. Manufacturing of ADCs: A Market Overview 6. CMOs: Worldwide Landscape 7. Profiles of Leading Companies 8. Recent Developments 9. Market Size and Forecast 10. SWOT Analysis 11. Conclusion 12. Interview Transcripts 13. Appendix 1: Tabulated Data 14. Appendix 2: List of Companies and Organisations Companies Mentioned - 35 of the 100 Companies - AAIPharma Services Corp - Ambrx - Amgen - AMRI Global - Aspyrian Therapeutics - Astellas Pharma/Agensys - Asymchem - Baxter BioPharma Solutions - Bayer Healthcare - Cambrex Corporation - CARBOGEN AMCIS - DSM Pharmaceuticals - EirGenix - Eli Lilly - Endo Pharmaceuticals - GSK - Heidelberg Pharma - Heraeus Precious Metals - iBIOSOURCE - Mersana Therapeutics - Millennium - MiMabs - National Cancer Institute - National Research Council Canada - NBE Therapeutics - Novartis - Pfizer/Wyeth - Philochem - Pierre Fabre - Redwood Bioscience - Roche/Genentech - SafeBridge Consultants - Sandoz - Sanofi - Zymeworks For more information visit http://www.researchandmarkets.com/research/sh...c_contract
ENDP: 64.27 (+0.85), CBM: 43.23 (-0.03), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), NVS: 91.90 (-0.71)
Liver Cirrhosis Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbjtw7/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H1, 2015" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H1, 2015" provides an overview of Liver Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Astellas Pharma - C. H. Boehringer Sohn - Conatus Pharmaceuticals - F. Hoffmann-La Roche - Genextra - GlaxoSmithKline - Merck & Co. - Novartis - Sanofi - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/zb..._cirrhosis
MRK: 50.95 (-0.07), CNAT: 4.21 (-0.06), GSK: 40.22 (+0.06), VRX.TO: 227.56 (+4.67), NVS: 91.90 (-0.71)
Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbnk43/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" report to their offering. This clinical trial report, Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" provides an overview of Herpes Zoster (Shingles) clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Astellas Pharma - Boehringer Ingelheim - GlaxoSmithKline - Hammersmith Medicines Research - Maruho - Merck & Co. - NeurogesX - Pfizer - Synergy Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pb...pes_zoster
SGYP: 6.32 (+0.18), MRK: 50.95 (-0.07), GSK: 40.22 (+0.06)
Zen & The Technology of Japanese Packaging Design Report 2015 - 2012-2014 Analysis of the $59 Billion Industry Featuring over 100 Manufacturers
M2 - Thu Sep 24, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g84x48/zen_and_the) has announced the addition of the "Zen & The Technology of Japanese Packaging Design 2012-14" report to their offering. The ultimate illustrated guide to current trends in Japan's US$59.4 billion product packaging market. This 202-page report examines changing consumer trends and the regulatory environment for all key packaging end-use markets - food, beverage, spirits, confectionery, cosmetics, personal care, household, pharmaceutical, medical, electronics, industrial and logistics - and all packaging materials, types and formats. Fully illustrated with more than 200 photographs of the latest innovative packaging technologies and solutions introduced in the Japanese market between 2012 and 2014 by more than 110 Japanese packaging manufacturers, design agencies and brand owners, Zen & The Technology of Japanese Packaging Design 2012-14 provides real-life market examples and case studies of how the Japanese packaging industry has responded to the changing market dynamic. Many of the product packaging solutions developed by Japanese industry are relevant in Western markets where packaging and brand owners are begining to encounter similar challenges of changing demographics, sustainability and increased regulatory regimens. Why Purchase this Report: - Understand the cultural cues underlying product packaging in Japan - Be inspired by the simplicity of minute market-oriented attention to detail - Find out how to sell to Japanese consumers, and by extension, other Asian markets - Gain knowledge about the impact of Japan's legislation on packaging design - See how the EU's Circular Economy Package, when passed, could impact packaging conceptualisation and production - Learn how sustainable packaging can be achieved without compromising design integrity - Discover an entirely new market niche by planning Accessibility and Universal Design into your production workflow - Be inspired by ideas for your own design project Key Topics Covered: 1. Introduction: A Narrow Road to the Deep North 2. Aesthetics & Zen 3. Referencing EDO 4. The Japanese Packaging Industry Structure: 5. Packaging the Environment 6. A Circular Economy 7. Marketing & the New Demographic 8. Universal Design 9. Japan's Retail Revolution 10. Packaging & Disaster Companies Mentioned - Partial List - Able Design - Ailop Corp - Ajinomoto - Aoki Laboratories Ltd - Asahi Breweries Ltd - Asahi Kasei Pax Corporation - Asahi Printing Co Ltd - Astellas Pharma Inc - Ito-Takaya Design Office Inc - Japan Gateway Co Ltd - Japan Packaging Institute - Japansalt Corporation - Johnson Co Ltd - J-Oil Mills Inc - Kabaya Confectionery Co Ltd - Kanpyo Corporation - Lion Corporation - Mitsubishi Shoji Packaging Corporation - Mottainai - Nabatame Design Co Ltd - Nakatsugawa Packaging Industrial Co Ltd - Nestle Japan Ltd - Nestl? Japan Ltd - Next Innovation Inc - Oji Container Co Ltd - Oji Paper Co Ltd - PacPlus Co Ltd - Takeda Sangyo Corporation Ltd - Teva Pharma Japan Inc - The Pack Corp - Three R Produce Inc - Toto Ltd - Toyo Seikan Kaisha Ltd - Yatsushika Brewery Co Ltd - Yoshida Cosmeworks Co Ltd For more information visit http://www.researchandmarkets.com/research/g8...en_and_the
GSVC: 8.26 (+0.05)
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 269.16 (-10.72), ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AVEO: 1.27 (+0.05), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
leon-nanodrugs GmbH Starts U.S. Operations and Appoints Industry Veteran Theron (Ted) Odlaug as Chief Executive Officer
PR Newswire Europe - Mon Sep 21, 1:00AM CDT
leon-nanodrugs GmbH today announced the appointment of industry veteran Theron (Ted) Odlaug, Ph.D. as the CEO for the leon-nanodrugs GmbH in Munich, Germany, and of its newly formed U.S. subsidiary leon-nanodrugs Inc., with offices in New York City and Chicago, Illinois. Recently, leon-nanodrugs successfully completed a Series A Financing round and announced using the proceeds to expand its profitable service business and to enter into high margin service and co-development deals with pharmaceutical partners.
AMRI: 17.28 (+0.08)
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
PR Newswire Europe - Fri Sep 18, 3:00AM CDT
CHERTSEY, England, September 18, 2015 /PRNewswire/ --
Astellas Pharma EMEA appoints Eugene Van Rensburg as Chief Financial Officer
M2 - Fri Sep 18, 2:45AM CDT
Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Eugene Van Rensburg to the position of Chief Financial Officer from his previous role as Senior Finance Director.
Jamie McGarvey joins Astellas Pharma Corporate Affairs Team
PR Newswire - Tue Sep 15, 3:00PM CDT
Astellas Pharma today announced that Jamie McGarvey has been named to the role of senior manager, employee communications within the Corporate Affairs Department. She will report to Jennifer Saputo, associate director of employee communications.
Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397
GlobeNewswire - Tue Sep 15, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present a poster summarizing results from preclinical studies of its antifungal compound, VL-2397 (formerly known as ASP2397), at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy joint meeting in San Diego, California. The poster, titled "Pharmacokinetic and Pharmacodynamic Characterization of ASP2397, a Novel Potent Antifungal Agent with Activity against Invasive Pulmonary Aspergillosis," will be presented during the "New Anti-Fungal Agents" poster session on September 19, 2015 from 11:00am to 1:00pm PT.
VICL: 0.43 (unch)
